The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Glucagon-Like Peptides
Abstract
Proglucagon contains the sequence of two glucagonlike peptides, GLP-1 and GLP-2, secreted from enteroendocrine cells of the small and large intestine. GLP-1 lowers blood glucose in both NIDDM and IDDM patients and may be therapeutically useful for treatment of patients with diabetes. GLP-1 regulates blood glucose via stimulation of glucose-dependent insulin secretion, inhibition of gastric emptying, and inhibition of glucagon secretion. GLP-1 may also regulate glycogen synthesis in adipose tissue and muscle; however, the mechanism for these peripheral effects remains unclear. GLP-1 is produced in the brain, and intracerebroventricular GLP-1 in rodents is a potent inhibitor of food and water intake. The short duration of action of GLP-1 may be accounted for in part by the enzyme dipeptidyl peptidase 4 (DPP-IV), which cleaves GLP-1 at the NH2-terminus; hence GLP-1 analogs or the lizard peptide exendin-4 that are resistant to DPP-IV cleavage may be more potent GLP-1 molecules in vivo. GLP-2 has recently been shown to display intestinal growth factor activity in rodents, raising the possibility that GLP-2 may be therapeutically useful for enhancement of mucosal regeneration in patients with intestinal disease. This review discusses recent advances in our understanding of the biological activity of the glucagon-like peptides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 5×
“Initial characterization of GLP1 bioactivity using NH,-terminally extended GLP-l(1-37) failed to demonstrate effects on blood glucose or insulin secretion; however, subsequent experiments using the NH,terminally truncated GLP-l(7-36) amide or GLP-l(7-37) peptides demonstrated potent effects on glucose-dependent insuli…”
BackgroundMethodInfluentialSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Schmidt, W. E., Siegel, E. G., & Creutzfeldt, W. (1985) · Diabetologia · doi:10.1007/bf00291980 · Cited by 319
Ørskov, C., Wettergren, A., & Holst, J. J. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609009147 · Cited by 271
Glucagonlike peptide 1: a newly discovered gastrointestinal hormone
Holst, J. J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90831-1 · Cited by 252
Role of prohormone convertases in the tissue-specific processing of proglucagon
Dhanvantari, S. (1996) · Molecular Endocrinology · doi:10.1210/me.10.4.342 · Cited by 242
Mammalian pancreatic preproglucagon contains three glucagon-related peptides.
Lopez, L. C., Frazier, M. L., Su, C. J., Kumar, A., & Saunders, G. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.18.5485 · Cited by 234
Reimer, R. A. (1996) · Endocrinology · doi:10.1210/en.137.9.3948 · Cited by 207
Balks, H. J., Holst, J. J., Mühlen, A. V. Z., & Brabant, G. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3816 · Cited by 179
Lee, Y. C., Asa, S. L., & Drucker, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50075-8 · Cited by 164
Self-citationGlucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic a cells
Efrat, S., Teitelman, G., Anwar, M., Ruggiero, D., & Hanahan, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90110-9 · Cited by 164
Jin, T., & Drucker, D. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.19 · Cited by 137
Self-citationGlucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM
Thorens, B., & Waeber, G. (1993) · Diabetes · doi:10.2337/diab.42.9.1219 · Cited by 133
Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides
Herrmann-Rinke, C., Vöge, A., Hess, M., & Göke, B. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1470025 · Cited by 130
Dumoulin, V., Dakka, T., Plaisancié, P., Chayvialle, J. A., & Cuber, J.-C. (1995) · Endocrinology · doi:10.1210/endo.136.11.7588257 · Cited by 111
Irwin, D. M., & Wong, J. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.3.7776976 · Cited by 101
Plaisancié, P., Dumoulin, V., Chayvialle, J. A., & Cuber, J.-C. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1450521 · Cited by 79
Rothenberg, M. E., Eilertson, C. D., Klein, K., Zhou, Y., Lindberg, I., McDonald, J. K., Mackin, R. B., & Noe, B. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.10136 · Cited by 76
Hoyt, E. C., Lund, P. K., Winesett, D. E., Fuller, C. R., Ghatei, M. A., Bloom, S. R., & Ulshen, M. H. (1996) · Diabetes · doi:10.2337/diab.45.4.434 · Cited by 59
Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum
Herrmann-Rinke, C., Hörsch, D., McGregor, G. P., & Göke, B. (1996) · Peptides · doi:10.1016/0196-9781(96)00072-1 · Cited by 37
Cited by
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Frühbeck, G., Gómez-Ambrosi, J., Muruzábal, F. J., & Burrell, M. A. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e827 · Cited by 974
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Metadata
- Authors
- Drucker, D. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1998-02-01
- Volume
- 47
- Issue
- 2
- Pages
- 159-169
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2100629874
- Cited by
- 601
- References
- 29
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.